[go: up one dir, main page]

CY1114499T1 - Βιοδιαθεσιμες στερεες δοσολογικες μορφες μεταξαλονης - Google Patents

Βιοδιαθεσιμες στερεες δοσολογικες μορφες μεταξαλονης

Info

Publication number
CY1114499T1
CY1114499T1 CY20131100902T CY131100902T CY1114499T1 CY 1114499 T1 CY1114499 T1 CY 1114499T1 CY 20131100902 T CY20131100902 T CY 20131100902T CY 131100902 T CY131100902 T CY 131100902T CY 1114499 T1 CY1114499 T1 CY 1114499T1
Authority
CY
Cyprus
Prior art keywords
dosage form
metaxalone
blade
rpm
stirred
Prior art date
Application number
CY20131100902T
Other languages
English (en)
Inventor
Spiridon Spireas
Original Assignee
Spiridon Spireas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spiridon Spireas filed Critical Spiridon Spireas
Publication of CY1114499T1 publication Critical patent/CY1114499T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μια φαρμακευτική στερεή δοσολογική μορφή περιλαμβάνει μεταξαλόνη και τουλάχιστον ένα έκδοχο σκόνης, όπου η μεταξαλόνη αναμειγνύεται σε ξηρή κατάσταση με το τουλάχιστον ένα έκδοχο σκόνης· το μείγμα μεταξαλόνης/σκόνης στη συνέχεια διαβρέχεται και κοκκοποιείται με τουλάχιστον ένα φαρμακευτικώς αποδεκτό πτητικό υγρό· και το υγρό κοκκοποίημα στη συνέχεια ξηραίνεται, αλέθεται και κατόπιν αναμειγνύεται με άλλα έκδοχα σκόνης για να δώσει το τελικό μείγμα μεταξαλόνης/σκόνης το οποίο στη συνέχεια συμπιέζεται για να παραχθεί η φαρμακευτική στερεή δοσολογική μορφή, και όπου: (i) 13% κατά βάρος ή περισσότερο της εν λόγω μεταξαλόνης διαλύεται περίπου 30 λεπτά από τη στιγμή που η εν λόγω δοσολογική μορφή τοποθετηθεί σε ένα αιχμηρό γυάλινο δοχείο διάλυσης πληρωμένο με 1000 mL απιονισμένου νερού, διατηρούμενο στους 25°C και αναδευόμενο σε μια ταχύτητα πτερυγίου 100 rpm χρησιμοποιώντας μια USP Τύπου II (πτερυγίου) συσκευή· ή (ii) 28% κατά βάρος ή περισσότερο της εν λόγω μεταξαλόνης διαλύεται περίπου 30 λεπτά από τη στιγμή που η εν λόγω δοσολογική μορφή τοποθετηθεί σε ένα πρότυπο γυάλινο δοχείο διάλυσης πληρωμένο με 1000 mL απιονισμένου νερού, διατηρούμενο στους 35°C και αναδευόμενο σε μια ταχύτητα πτερυγίου 100 rpm χρησιμοποιώντας μια USP Τύπου II (πτερυγίου) συσκευή· ή (iii) 27% κατά βάρος ή περισσότερο της εν λόγω μεταξαλόνης διαλύεται περίπου 30 λεπτά από τη στιγμή που η εν λόγω δοσολογική μορφή τοποθετηθεί σε ένα αιχμηρό γυάλινο δοχείο διάλυσης πληρωμένο με 500 mL ενός υδατικού διαλύματος 0.1% κατά βάρος Λαυρυλοθειικού Νατρίου ανά όγκο νερού, διατηρούμενο στους 37°C και αναδευόμενο σε μια ταχύτητα πτερυγίου 50 rpm χρησιμοποιώντας μια USP Τύπου II (πτερυγίου) συσκευή.
CY20131100902T 2004-03-08 2013-10-15 Βιοδιαθεσιμες στερεες δοσολογικες μορφες μεταξαλονης CY1114499T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55125704P 2004-03-08 2004-03-08
EP09165833.6A EP2110124B1 (en) 2004-03-08 2005-03-08 Bioavailable Solid Dosage Forms of Metaxalone

Publications (1)

Publication Number Publication Date
CY1114499T1 true CY1114499T1 (el) 2016-10-05

Family

ID=34964783

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100902T CY1114499T1 (el) 2004-03-08 2013-10-15 Βιοδιαθεσιμες στερεες δοσολογικες μορφες μεταξαλονης

Country Status (11)

Country Link
US (7) US20050276844A1 (el)
EP (2) EP1755559A1 (el)
CN (2) CN103284965A (el)
AU (1) AU2005221659B2 (el)
CA (1) CA2563739C (el)
CY (1) CY1114499T1 (el)
DK (1) DK2110124T3 (el)
ES (1) ES2430849T3 (el)
MX (1) MXPA06010146A (el)
NZ (1) NZ588259A (el)
WO (1) WO2005087204A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
EP1965795A2 (en) * 2005-12-29 2008-09-10 Teva Pharmaceutical Industries Ltd. Metaxalone formulations and methods for the preparation thereof
US20120093928A1 (en) * 2007-08-09 2012-04-19 Ranbaxy Laboratories Limited Oral metaxalone compositions
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
AP2015008955A0 (en) 2009-04-24 2015-12-31 Icuetica Pty Ltd A novel formulation of indomethacin
NZ595903A (en) * 2009-04-24 2014-03-28 Iceutica Pty Ltd A novel formulation of metaxalone
CN102232938B (zh) * 2010-05-06 2014-06-11 杭州赛利药物研究所有限公司 美他沙酮胶囊及其制备方法
JP6453876B2 (ja) * 2013-07-22 2019-01-16 イシューティカ インコーポレイテッド メタキサロンの製剤
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2019217286A1 (en) * 2018-05-07 2019-11-14 Prana Biosciences Inc Metaxalone formulations
CN109157527B (zh) * 2018-07-25 2021-05-04 珠海润都制药股份有限公司 一种厄贝沙坦胶囊及其制备方法
US20200405693A1 (en) * 2019-06-25 2020-12-31 Primus Pharmaceuticals, Inc. Reduced dose metaxalone formulations
US11918559B2 (en) * 2019-06-25 2024-03-05 Primus Pharmceuticals, Inc. Reduced dose metaxalone formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993767A (en) * 1975-11-18 1976-11-23 A. H. Robins Company, Incorporated Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy
US4036957A (en) * 1975-11-18 1977-07-19 A. H. Robins Company, Inc. Phenoxy compounds in combinations to suppress gastric bleeding in aspirin therapy
JP3766468B2 (ja) * 1996-04-18 2006-04-12 麒麟麦酒株式会社 レーザ印字用媒体
US5800834A (en) * 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6096337A (en) 1996-06-10 2000-08-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
DE19930143C1 (de) * 1999-06-30 2001-07-12 Wincor Nixdorf Gmbh & Co Kg Geräteanordnung mit einer in einem Gehäuse gehaltenen Baugruppe
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
EP1651189B1 (en) * 2003-08-08 2008-12-03 Elan Pharma International Limited Novel metaxalone compositions

Also Published As

Publication number Publication date
CA2563739C (en) 2013-07-09
US20110124694A1 (en) 2011-05-26
US20160158203A1 (en) 2016-06-09
MXPA06010146A (es) 2007-05-11
EP2110124B1 (en) 2013-07-17
CN1980642A (zh) 2007-06-13
US20150352080A1 (en) 2015-12-10
EP2110124A1 (en) 2009-10-21
EP1755559A1 (en) 2007-02-28
US20050276844A1 (en) 2005-12-15
US20130245083A1 (en) 2013-09-19
AU2005221659B2 (en) 2008-07-03
CN103284965A (zh) 2013-09-11
AU2005221659A1 (en) 2005-09-22
NZ588259A (en) 2012-09-28
US20100099723A1 (en) 2010-04-22
US20130245082A1 (en) 2013-09-19
WO2005087204A1 (en) 2005-09-22
CA2563739A1 (en) 2005-09-22
DK2110124T3 (da) 2013-10-21
ES2430849T3 (es) 2013-11-22

Similar Documents

Publication Publication Date Title
CY1114499T1 (el) Βιοδιαθεσιμες στερεες δοσολογικες μορφες μεταξαλονης
PA8565501A1 (es) Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
PE20020968A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
RU2004114225A (ru) Перорально вводимые жидкие композиции, включающие гвайфенезин и блок-сополимеры полиоксиалкилена
UY26496A1 (es) Composiciones farmacéuticas que proporcionan concentraciones potenciadas de fármaco
DE60139907D1 (de) Pharmazeutische Zubereitung enthaltend Drospirenon
JP2005500309A5 (el)
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
NO20062945L (no) Forlenget anvendelseskombinasjon omfattende ostrogener og progestiner
ATE16683T1 (de) Verwendung eines copolymeren aus acrylsaeure und maleinsaeure als anmischkomponente fuer glasionomerzemente.
EA201490802A1 (ru) Препараты этанерцепта, стабилизированные меглюмином
HRP20210242T1 (hr) Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
DE69906084D1 (de) Ibuprofen enthaltende schnelllösliche zusammensetzungen mit analgetischer wirkung
AR117718A2 (es) Mejoramientos en composiciones farmacéuticas, y relacionados con ellas
IL179718A0 (en) Pharmaceutical composition containing irbesartan
Mungara et al. Comparative evaluation of fluoride release and recharge of pre-reacted glass ionomer composite and nano-ionomeric glass ionomer with daily fluoride exposure: An: in vitro: study
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
EA200600528A1 (ru) Способ получения водорастворимых дитерпенов и их применение
ATE424192T1 (de) Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten
MXPA05014232A (es) Composiciones farmaceuticas estables de 5,10-metilentetrahidrofolato.
BRPI0407649A (pt) formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
EA201070766A1 (ru) Стабильные при комнатной температуре лиофилизированные композиции натрийуретического пептида
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
AR036185A1 (es) Producto antitranspirante con dibencilideno sorbitol y elastomero en dimeticona